Part I Basic Ideas of Managed Care |
|
|
1 Definitions and Concepts |
|
|
3 | (14) |
|
1.1 Supporting and Inhibiting Factors of Managed Care |
|
|
3 | (3) |
|
1.2 Definitions of Managed Care |
|
|
6 | (3) |
|
1.3 Which Instruments and Organisational Forms Belong to Managed Care9 |
|
|
9 | (2) |
|
1.4 What Changes for Those Involved in the Managed Care Context? |
|
|
11 | (2) |
|
|
13 | (4) |
|
2 Main Characteristics of the American Healthcare System |
|
|
17 | (10) |
|
|
17 | (5) |
|
2.1.1 Government and Compulsory Contribution Schemes |
|
|
18 | (2) |
|
2.1.2 Private Healthcare Coverage Plans |
|
|
20 | (2) |
|
2.2 Delivering Healthcare Services |
|
|
22 | (1) |
|
2.3 Receiving Healthcare Services |
|
|
23 | (1) |
|
|
24 | (3) |
|
3 Theoretical Concepts for the Assessment of Managed Care |
|
|
27 | (18) |
|
3.1 Transaction Cost Theory |
|
|
27 | (2) |
|
|
27 | (1) |
|
|
28 | (1) |
|
3.2 Reasons for Market Failure: Williamson's Organisational Failure Framework of 1975 |
|
|
29 | (4) |
|
3.2.1 Market, Hierarchy or Cooperations |
|
|
31 | (1) |
|
3.2.2 The Suitability of Transaction Cost Theory in Healthcare |
|
|
32 | (1) |
|
3.3 Principal-Agent Theory |
|
|
33 | (2) |
|
3.4 Information Asymmetries and Behavioural Uncertainties |
|
|
35 | (5) |
|
3.4.1 Coordination Patterns |
|
|
37 | (3) |
|
3.4.2 Principal-Agent Theory for the Analysis of Steering Elements in Healthcare |
|
|
40 | (1) |
|
|
40 | (5) |
Part II Managed Care Organisations and Products |
|
|
|
45 | (4) |
|
|
48 | (1) |
|
5 Insurance-Based Managed Care Organisations and Products |
|
|
49 | (18) |
|
5.1 Staff, Group, IPA and Network Model HMOs |
|
|
49 | (11) |
|
|
49 | (2) |
|
|
51 | (2) |
|
|
53 | (5) |
|
|
58 | (1) |
|
|
58 | (2) |
|
5.2 Consumer-Driven Health Plans (CDHPs) and Health Savings Accounts |
|
|
60 | (4) |
|
5.2.1 Guidelines and Health Policy Goals |
|
|
60 | (1) |
|
5.2.2 Forms and Prevalence |
|
|
61 | (2) |
|
|
63 | (1) |
|
|
64 | (3) |
|
6 Provider-Based Managed Care Organisations and Products |
|
|
67 | (20) |
|
6.1 Independent Practice Associations (WA) |
|
|
67 | (1) |
|
6.2 Preferred Provider Organisations (PPO) |
|
|
68 | (1) |
|
|
69 | (3) |
|
6.4 Integrated Delivery Systems (IDS) |
|
|
72 | (8) |
|
6.5 Accountable Care Organisations (ACO) |
|
|
80 | (1) |
|
6.6 Patient-Centred Medical Homes (PCMH) |
|
|
81 | (2) |
|
|
83 | (4) |
|
7 Institutions in the Managed Care Environment |
|
|
87 | (10) |
|
7.1 Management Service Organisations (MSO) |
|
|
87 | (2) |
|
7.2 Physician Practice Management Companies (PPMC) |
|
|
89 | (1) |
|
7.3 Pharmacy Benefit Management (PBM) |
|
|
90 | (4) |
|
7.3.1 Elements of Pharmacy Benefit Management (PBM) |
|
|
91 | (3) |
|
|
94 | (1) |
|
|
94 | (3) |
|
|
97 | (6) |
|
|
99 | (4) |
Part III Managed Care Instruments |
|
|
|
103 | (16) |
|
9.1 Selective Contracting |
|
|
103 | (5) |
|
9.1.1 Introductory Remarks |
|
|
103 | (1) |
|
9.1.2 Selective Contracts with Physicians |
|
|
104 | (2) |
|
9.1.3 Selective Contracts with Hospitals |
|
|
106 | (1) |
|
9.1.4 Assessment of Selective Contracting |
|
|
107 | (1) |
|
9.2 Structuring the Insurance Contracts |
|
|
108 | (8) |
|
|
108 | (1) |
|
9.2.2 Options for Managing Pre-contract Risks |
|
|
108 | (1) |
|
9.2.3 Options for Managing Post-contract Risks |
|
|
109 | (6) |
|
|
115 | (1) |
|
|
116 | (3) |
|
|
119 | (30) |
|
|
119 | (3) |
|
10.2 Forms of Compensation |
|
|
122 | (11) |
|
|
123 | (1) |
|
10.2.2 Factor Cost Reimbursement |
|
|
123 | (1) |
|
|
124 | (1) |
|
10.2.4 Daily Rates (Per Diem) |
|
|
125 | (1) |
|
10.2.5 Case Rates and Diagnosis Related Groups (DRGs) |
|
|
126 | (2) |
|
|
128 | (3) |
|
|
131 | (2) |
|
10.3 Pay-for-Performance (P4P) and Public Reporting |
|
|
133 | (9) |
|
10.3.1 Pay-for-Performance |
|
|
133 | (2) |
|
10.3.2 Design of the Model |
|
|
135 | (4) |
|
|
139 | (1) |
|
|
139 | (2) |
|
10.3.5 Negative Incentives |
|
|
141 | (1) |
|
|
142 | (1) |
|
|
143 | (6) |
|
|
149 | (46) |
|
11.1 Guidelines and Clinical Pathways |
|
|
149 | (7) |
|
|
149 | (2) |
|
11.1.2 Forms and Objectives of Guidelines |
|
|
151 | (1) |
|
11.1.3 Areas of Application for Guidelines |
|
|
152 | (1) |
|
|
153 | (3) |
|
11.2 Disease Management and Chronic Care |
|
|
156 | (10) |
|
11.2.1 Introductory Remarks |
|
|
156 | (1) |
|
11.2.2 Elements of Disease Management |
|
|
157 | (1) |
|
11.2.3 Stages of Disease Management |
|
|
158 | (3) |
|
11.2.4 Chronic Care Model |
|
|
161 | (3) |
|
11.2.5 Critical Assessment of Disease Management and Chronic Care Management |
|
|
164 | (2) |
|
|
166 | (6) |
|
|
166 | (2) |
|
11.3.2 Range of Tasks of the Case Manager |
|
|
168 | (2) |
|
11.3.3 Case Management Procedure |
|
|
170 | (1) |
|
11.3.4 Evaluating Case Management |
|
|
171 | (1) |
|
|
172 | (5) |
|
11.4.1 Specifications of Patient Coaching |
|
|
173 | (3) |
|
|
176 | (1) |
|
11.5 Principles of Managed Care |
|
|
177 | (10) |
|
11.5.1 Preliminary Remarks |
|
|
177 | (1) |
|
11.5.2 Quality Planning ("Plan") |
|
|
178 | (5) |
|
11.5.3 Quality Implementation ("Do") |
|
|
183 | (1) |
|
11.5.4 Quality Inspection ("Check") |
|
|
183 | (3) |
|
11.5.5 Implementation of Quality Improvement Measures ("Act") |
|
|
186 | (1) |
|
|
186 | (1) |
|
|
187 | (8) |
|
|
195 | (18) |
|
|
195 | (4) |
|
|
195 | (1) |
|
12.1.2 Forms of Gatekeeping |
|
|
196 | (1) |
|
12.1.3 Significance and Mechanisms |
|
|
197 | (1) |
|
|
198 | (1) |
|
|
199 | (4) |
|
12.2.1 Fundamental Concepts and Effective Mechanisms |
|
|
199 | (2) |
|
12.2.2 Goals of Implementing Formularies |
|
|
201 | (1) |
|
|
202 | (1) |
|
12.3 Utilisation Review and Management |
|
|
203 | (6) |
|
|
204 | (1) |
|
12.3.2 Forms of Utilisation Review and Utilisation Management |
|
|
205 | (2) |
|
12.3.3 Importance and Effective Mechanisms |
|
|
207 | (1) |
|
|
208 | (1) |
|
|
209 | (4) |
|
|
213 | (28) |
|
|
213 | (1) |
|
13.2 Health Economic Evaluation |
|
|
214 | (7) |
|
|
215 | (1) |
|
13.2.2 Cost-Effectiveness Analysis |
|
|
216 | (1) |
|
13.2.3 Cost-Utility Analysis |
|
|
217 | (2) |
|
13.2.4 Cost-Benefit Analysis |
|
|
219 | (1) |
|
13.2.5 Sensitivity Analysis |
|
|
220 | (1) |
|
13.3 Preference Measurement |
|
|
221 | (7) |
|
13.3.1 Patient Benefits and Preferences |
|
|
221 | (1) |
|
13.3.2 Measurement of Preferences |
|
|
222 | (1) |
|
13.3.3 The Foundational Methods: The Conjoint Analysis (CA) |
|
|
223 | (1) |
|
13.3.4 The Discrete Choice Experiment |
|
|
223 | (4) |
|
|
227 | (1) |
|
13.4 Evidence-Based Medicine (EBM) |
|
|
228 | (3) |
|
13.4.1 Systematic Acquisition of Information |
|
|
229 | (1) |
|
13.4.2 Analysis of the Evidence |
|
|
230 | (1) |
|
13.4.3 Application of Evidence Found in Individual Cases |
|
|
230 | (1) |
|
13.5 Health Services Research |
|
|
231 | (2) |
|
13.6 Health Technology Assessment (HTA) |
|
|
233 | (2) |
|
|
235 | (6) |
Part IV Evaluation of Managed Care |
|
|
|
241 | (4) |
|
|
242 | (3) |
|
15 Cost Effects of Managed Care |
|
|
245 | (2) |
|
|
246 | (1) |
|
16 Quality Effects of Managed Care |
|
|
247 | (4) |
|
|
249 | (2) |
|
17 Access Effects of Managed Care |
|
|
251 | (2) |
|
|
252 | (1) |
|
18 Acceptance of Managed Care |
|
|
253 | (4) |
|
18.1 Acceptance from the Insured and Patients |
|
|
253 | (1) |
|
18.2 Acceptance from Physicians |
|
|
254 | (1) |
|
|
254 | (3) |
|
|
257 | (2) |
|
|
258 | (1) |
Index |
|
259 | |